Abstract 672: TumoraseTM: In vivo efficacy data for novel localized proteinase treatment applicable to solid tumors of varied tissue origins

Abstract

Abstract To facilitate the development of noninvasive solid tumor cancer treatments, BioMedicure reports here the development of a specific proteinase treatment that when injected locally into solid tumors elicits a substantial tumor remission. Reported here is data indicating that intratumoral injection of TumoraseTM (T101, BioMedicure, San Diego, CA), a novel proteinase formulation, into solid tumors of various tissue origin destroys the tumor by digesting the solid-structure, killing cancer cells, including cancer stem cells, locally while not effecting normal tissues. The best route of TumoraseTM biochemical delivery to the tumor is intratumoral injection by a needle with a gauge 20-27. Before TumoraseTM intratumoral delivery, the tumor volume is estimated by 3-dimensional measurement and calculation: L x W X H in mm3, where “L” is the solid-tumor length, “W” solid-tumor width and “H” solid-tumor height. Tumorase works best when intratumorally injected at about 50-80% of solid-tumor volume delivered not by bolus but at about 200 uL per minute. The success rate of eliminating sparsely vascularized solid-tumors 50-400 mm3 in volume is high (over 70%). However, since inhibitory factors in serum diminish the activity of TumoraseTM, the success rate of eliminating a highly vascularized soft or liquid tumor is low (below 30%), though partial tumor mass decrease responses are observed. Multiple treatments can be applied to further diminish tumor mass. Data will be presented for the following tumor models, the human melanoma (CRL-1676 and WM-266-4), the human prostates (CRl-2505 and 22Rv1), human breast ductal carcinomas (HTB-129 and MDA-MB-435S), the human bronchioalveolar carcinomas (HTB-177 and NCI-H460) and the human colon adenocarcinomas (CCL-231 and SW48) xenografts. When a cancerous growth is found early and is accessible by a surgical knife, surgery is still the recommended treatment. However, if not accessible or there are multiple tumors, then, TumoraseTM would be a viable option, a local therapy that can be utilized for multiple tumors elimination. TumoraseTM contains proteases that cleave the extracellular matrix, including vital proteins required for cell survival, leading to cancer cell death. Presented here is in vivo data indicating the efficacy of this novel proteinase preparation for the elimination of solid tumors of multiple tumor classes by destroying tumors’ solid structure and killing cancer cells by cleaving the extracellular domains of vital cell membrane proteins. The wide range of solid cancerous tumors eliminated suggests a potential wide clinical applicability. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 672.